Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Vasectomy and prostate cancer: Myth or reality?

Choosing the best treatment of prostate cancer - by stage

What is benign prostatic hyperplasia?

Prostate Cancer Diagnosis

Precancerous conditions of the prostate

Hormonal therapy for prostate cancer

Radiation therapy for prostate cancer

Gold Nanoparticles Use in Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Palliative treatment and end of life care for prostate cancer

Prostate Cancer Partin Tables

See more featured articles »

What is medical castration?

Treatment of prostatitis

Prostate Cancer Questions

Symptoms of Benign Prostatic Hyperplasia (BHP)

What is Prostatitis?

Prostate Cancer Epidemiology

What is TURP?

Prostate Cancer and Genetics

Prostate Cancer and Diet

Prostatitis symptoms

Prostate Cancer Research

What is Prostatectomy?

Survival rates of prostate cancer

Brachytherapy for Prostate Cancer

Prostate Cancer Risk Factors

Diagnosis of Benign Prostatic Hyperplasia (BPH)

The Prostate

What is the PSA Test?

Causes of prostatitis

Differentiating between prostate cancer and prostate enlargement

Prostate cancer complications

PSA False Positive and False Negative Results

What Should You Avoid Before a PSA Test?

Prostate Cancer Treatment

What is the Gleason Score?

PSA Test in Men Who Have Been Treated for Prostate Cancer

Prostate Cancer Cell Dormancy and Activation

Rectal Examination for Prostate Cancer

Treatment of Benign Prostatic Hyperplasia (BHP)

Breakthroughs in Prostate Cancer Treatments

Prostate Biopsy

Prostate Cancer Staging

Types of PSA Test

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Life after prostate cancer treatment

Prostate Cancer Epidemiology Worldwide

The International Prostate Symptoms Score (IPSS)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer Symptoms

Recent Genetic Breakthroughs in Prostate Cancer Research

What is the PCA3 Test?

Diagnosis of prostatitis

Prostate cancer alternative and complementary therapies

Prostate Cancer and Exercise

Single Nucleotide Polymorphisms and Prostate Cancer

Prostate cancer prevention

Causes of benign prostatic hyperplasia

Cryosurgery for prostate cancer

Prostate Cancer Screening

Latest Prostate Cancer News and Research

Imaging scans detect prostate cancer progression despite stable PSA levels

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.

1 Jul 2026

Monoclonal antibody shows promise for treating acute respiratory distress syndrome

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS.

30 Jun 2026

Study links DNA methylation to aggressive prostate cancer behavior

The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million American men, with another 330,000 men expected to be diagnosed with the condition this year alone.

30 Jun 2026

Weak handgrip may not independently predict prostate cancer risk

New research suggests that low handgrip strength alone is not a reliable predictor of increased prostate cancer risk among older men.

28 Jun 2026

New Florida initiative supports healthier lives for cancer survivors statewide

University of West Florida Assistant Professor of Public Health Dr. Karishma Chhabria Unrue has been awarded a nearly $825,000 grant through the Florida Cancer Innovation Fund to lead a statewide initiative focused on improving the health and well-being of breast and prostate cancer survivors.

27 Jun 2026

Stockholm3 blood test may offer more accurate prostate cancer detection

...

23 Jun 2026

Mount Sinai study connects social determinants of health to disease risks

A new study from the Icahn School of Medicine at Mount Sinai shows that social determinants of health-including environmental conditions, health behaviors, access to resources, and social well-being-can play an equally important or even greater role than genetics in predicting a person's risk of developing common diseases.

22 Jun 2026

New study uncovers how prostate cancer cells evade treatment

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

16 Jun 2026

Purdue develops next-generation platform to accelerate cancer drug discovery

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

16 Jun 2026

Engineered silica nanoparticles destroy prostate tumors in preclinical study

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell College of Engineering.

15 Jun 2026

Light-controlled molecular switch wakes lung cancer cells for treatment

Researchers from ETH Zurich have developed a molecular switch that is controlled by light. It wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment.

15 Jun 2026

Study finds gaps in guideline-based testosterone prescribing practices

Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.

14 Jun 2026

NYU Langone hits milestone with its 1,000th focal cryotherapy procedure

Just two days after his minimally invasive prostate cancer treatment at NYU Langone Health, Broadway performer André De Shields, 80, was back onstage preparing for his next show, Cats: The Jellicle Ball, which debuted in April 2026.

5 Jun 2026

Novel theranostic approach targets aggressive neuroendocrine prostate cancer

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy.

2 Jun 2026

PSMA PET detects high-risk prostate cancer bone metastases

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.

1 Jun 2026

Predictive model helps tailor PSMA therapy for prostate cancer patients

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.

31 May 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026